Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZTS with free AI briefings, catalyst countdowns, and dilution alerts.

ZTS · Zoetis Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash on Hand
CF+ Cash Runway
Follow ZTS by email Get an email when ZTS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZTS, unsubscribe in one click. Privacy

📣 What ZTS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

ZTS holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZTS files for a raise →

👥 Who Owns ZTS

Insiders 0% Institutions (1983 holders) 100% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 37,660,315 9.27% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 30,277,753 7.45% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 24,070,531 5.92% 2026-03-31
Michael B Mccallister
Director
Insider 31,893 0.01% 2026-06-10
Louise M Parent
Director
Insider 28,394 0.01% 2026-05-20
Paul Bisaro
Director
Insider 27,862 0.01% 2026-05-13
Frank A Damelio
Director
Insider 21,458 0.01% 2026-08-07
Julie Fuller
Executive Vice President · +3,997 options
Insider 1,588 0.00% 2026-09-30
Mark Stetter
Director · +2,830 options
Insider 1,572 0.00% 2026-05-21
Kevin Esch
Executive Vice President · +1,211 options
Insider 702 0.00% 2026-04-30

Share count 406,316,147 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ZTS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZTS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.